报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-09-30 | 32.55% | 2.17% | -0.46% | 115/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
2024-06-30 | 32.7% | 3.06% | 2.09% | 115/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
2024-03-31 | 32.03% | -2.54% | -1.15% | 114/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
2023-12-31 | 32.4% | 1.56% | 1.7% | 115/160 | 51.37% | 迈威生物 | 98.93% | 行业排名> |
2023-09-30 | 31.86% | 0.27% | 0.41% | 115/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
2023-06-30 | 31.73% | -3.03% | -3.45% | 120/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
2023-03-31 | 32.86% | -2.73% | 3.01% | 114/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
2022-12-31 | 31.9% | 3.97% | 0.41% | 119/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
2022-09-30 | 31.77% | 1.61% | -2.9% | 111/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
2022-06-30 | 32.72% | 0.56% | -3.14% | 115/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
2022-03-31 | 33.78% | -2.78% | 10.09% | 104/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
2021-12-31 | 30.69% | -7.16% | -1.87% | 126/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
2021-09-30 | 31.27% | -8.98% | -3.9% | 110/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
2021-06-30 | 32.54% | -9.34% | -6.36% | 118/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
2021-03-31 | 34.75% | -14.08% | 5.14% | 98/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
2020-12-31 | 33.05% | 3.14% | -3.8% | 125/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
2020-09-30 | 34.36% | 6.23% | -4.28% | 103/160 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
2020-06-30 | 35.89% | 7.63% | -11.25% | 107/160 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
2020-03-31 | 40.44% | 16.05% | 26.2% | 82/160 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
2019-12-31 | 32.05% | 10.55% | -0.91% | 117/160 | -1204.25% | 微芯生物 | 95.81% | 行业排名> |
2019-09-30 | 32.34% | 9.57% | -3.02% | 92/160 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
2019-06-30 | 33.35% | 9.68% | -4.31% | 97/160 | 55.36% | 微芯生物 | 96.11% | 行业排名> |
2019-03-31 | 34.85% | 10.09% | 20.22% | 87/160 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
2018-12-31 | 28.99% | 10.97% | -1.78% | 120/160 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
2018-09-30 | 29.51% | 12.81% | -2.92% | 91/160 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
2018-06-30 | 30.4% | 14.17% | -3.95% | 93/160 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
2018-03-31 | 31.65% | 12.43% | 21.18% | 85/160 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
2017-12-31 | 26.12% | 7.61% | -0.16% | 112/160 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
2017-09-30 | 26.16% | 3.7% | -1.75% | 87/160 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
2017-06-30 | 26.63% | 0.81% | -5.42% | 88/160 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
2017-03-31 | 28.15% | -0.39% | 15.99% | 67/160 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
2016-12-31 | 24.27% | 1.24% | -3.79% | 101/160 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
2016-09-30 | 25.23% | 3.62% | -4.48% | 69/160 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
2016-06-30 | 26.41% | 4.9% | -6.55% | 76/160 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
2016-03-31 | 28.27% | 4.1% | 17.89% | 60/160 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
2015-12-31 | 23.98% | 9.08% | -1.52% | 90/160 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
2015-09-30 | 24.35% | 9.46% | -3.31% | 65/160 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
2015-06-30 | 25.18% | 7.73% | -7.26% | 67/160 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
2015-03-31 | 27.15% | 12.38% | 23.53% | 54/160 | 43.46% | 舒泰神 | 94.4% | 行业排名> |